Long lived and unconventional PET radionuclides

Molecular Imaging in Oncology

Volumn , Issue , 2008, Pages 283-292

  Lewis, Jason S ^a   Singh, Rajendra K ^b   Welch, Michael J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84930247162     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (93)

1. Welch MJ, Redvanly CS, eds. Handbook of Radiopharmaceuticals. Chichester, West Sussex: John Wiley & Sons, 2003.
2. Schubiger PA, Lehmann L, Friebe M, eds. PET Chemistry: The Driving Force of Molecular Imaging. Ernst Schering Research Foundation Workshop. Vol. 62. Berlin: Springer, 2007.
3. McQuade P, Rowland DJ, Lewis JS, et al. Positron-emitting isotopes produced on biomedical cyclotrons. Curr Med Chem 2005; 12:807-818.
4. Lucignani G. Non-standard PET radionuclides: time to get ready for new clinical PET strategies. Eur J Nucl Med Mol Imaging 2007; 34:294-300.
5. Blower PJ, Lewis JS, Zweit J. Copper radionuclides and radiopharmaceuticals in nuclear medicine. Nucl Med Biol 1996; 23:957-980.
6. Glaser M, Mackay DB, Ranicar ASO, et al. Improved targetry and production of iodine-124 for PET studies. Radiochim Acta 2004; 92:951-956.
7. Glaser M, Luthra SK, Brady F. Applications of positron-emitting halogens in PET oncology. Int J Oncol 2003; 22:253-268.
8. Anderson CJ, Dehdashti F, Cutler PD, et al. Cu-64-TETA-Octreotide as a PET imaging agent for patients with neuroendocrine tumors. J Nucl Med 2001; 42:213-221.
9. 64Cu using a biomedical cyclotron. Nucl Med Biol 1997; 24:35-43.
10. 64Cu]Cu-ATSM for PET studies. Radiochim Acta 2005; 93:239-244.
11. 64Cu from a proton irradiated enriched nickel target. Appl Radiat Isot 2002; 57:773-777.
12. 64Cu on the Sherbrooke TR-PET cyclotron. J Radioanal Nucl Chem 2003; 257:175-177.
13. 64Cu using a 12 MeV cyclotron. Nucl Med Biol 2003; 30:535-539.
14. 64Cu at a small cyclotron. Appl Radiat Isot 1993; 44:575-580.
15. 64Ni target for positron emission tomography. Appl Radiat Isot 1991; 42:193-197.
16. McCarthy DW, Bass LA, Cutler PD, et al. High purity production and potential applications of copper-60 and copper-61. Nucl Med Biol 1999; 26:351-358.
17. Fan X, Parker DJ, Smith MD, et al. A simple and selective method for the separation of Cu radioisotopes from nickel. Nucl Med Biol 2006; 33:939-944.
18. 66Ga as an isotope for PET imaging and quantification. Med Phys 1997; 24:317-326.
19. 66Ga and labeling of antimyosin antibody for positron imaging of acute myocardial infarction. Eur J Nucl Med 1990; 16:237-240.
20. Ugur O, Kothari PJ, Finn RD, et al. Ga-66 labeled soma-tostatin analogue DOTA-DPhe1-Tyr3-octreotide as a potential agent for positron emission tomography imaging and receptor mediated internal radiotherapy of somatostatin receptor positive tumors. Nucl Med Biol 2002; 29: 147-157.
21. 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuti-cals. Nucl Med Biol 2003; 30:725-731.
22. 66Ga]bleomycin complex as a possible PET radiophar-maceutical. J Radioanal Nucl Chem 2005; 264:617-621.
23. Lewis MR, Reichert DE, Laforest R, et al. Production and purification of gallium-66 for preparation of tumor-targeting radiopharmaceuticals. Nucl Med Biol 2002; 29:701-706.
24. 67Ga. Appl Radiat Isot 1971; 22:710-713.
25. Brown LC, Callahan AP, Skidmore MR, et al. High-yield zinc-68 cyclotron targets for carrier-free gallium-67 production. Appl Radiat Isot 1973; 24:651-655.
26. Jennewein M, Qaim SM, Hermanne A, et al. A new method for radiochemical separation of arsenic from irradiated germanium oxide. Appl Radiat Isot 2005; 63:343-351.
27. 3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family. Tissue Antigens 1999; 54:597-602.
28. Phillips DR, Hamilton VT, Taylor WA, et al. Generator-produced arsenic-72 positron emission tomography. Radio-act Radiochem 1991; 3:53-58.
29. 72As radionuclide generator based on distillation. Radiochim Acta 2004; 92:245-249.
30. Basile D, Birattari C, Bonardi M, et al. Excitation functions and production of arsenic radioisotopes for environmental toxicology and biomedical purposes. Int J Appl Radiat Isot 1994; 32:403-110.
31. 2-receptor ligands. J Nucl Med 2006; 47:1041-1048.
32. Lee H, Finck BN, Jones LA, et al. Synthesis and evaluation of a bromine-76-labeled PPARg antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nucl Med Biol 2006; 33: 847-854.
33. 76Br-FBAU as a PET reporter probe for HSV1-tk gene expression imaging using mouse models of human glioma. J Nucl Med 2005; 46:1923-1930.
34. Szajek LP, Kao C-HK, Kiesewetter DO, et al. Semi-remote production of Br-76 and preparation of high specific activity radiobrominated pharmaceuticals for PET studies. Radiochim Acta 2004; 92:291-295.
35. Bergström M, Lu L, Fasth KJ, et al. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. J Nucl Med 1998; 39:1273-1279.
36. Lovquist A, Sundin A, Ahlstro H, et al. Pharmacokinetics and experimental PET imaging of a bromine-75-labeled monoclonal anti-CEA antibody. J Nucl Med 1997; 38: 395-401.
37. 76Br by a low-energy cyclotron. Appl Radiat Isot 1998; 49:1537-1540.
38. 76Br]FBAU 3'5'-dibenzoate as a lipophilic prodrug for brain imaging. Nucl Med Biol 2002; 29:527-535.
39. 79Br using packed capillary liquid chromatography mass spectrometry. Nucl Med Biol 2000; 27:851-853.
40. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996; 37:1557-1562.
41. 124Iodo-deoxyuridine measure cell proliferation in NSCLC? Initial investigations with PET imaging and radio-metabolite analysis. Eur J Nucl Med Mol Imaging 2007; 34:301-303.
42. 124I. Appl Radiat Isot 2001; 55:303-308.
43. 124Iatasmall cyclotron. Appl Radiat Isot 1995; 46:255-259.
44. 120gI at a small-sized cyclotron. Appl Radiat Isot 2003; 58:69-78.
45. Sheh Y, Koziorowski J, Balatoni J, et al. Low energy cyclotron production and chemical separation of "no carrier added" iodine-124 from a reusable, enriched tellurium-124 dioxide/aluminum oxide solid solution target. Radiochim Acta 2000; 88:169-173.
46. 3. Fifth International Symposium on Radiohalogens. Canada: Whistler, BC, 2004.
47. 75Br reaction at a compact cyclotron. Int J Appl Radiat Isot 1985; 36:635-42.
48. 2 targets. Appl Radiat Isot 2000; 52:181-184.
49. 124I]-iodine on an 11 MeV cyclotron. Radiochim Acta 2006; 94:213-216.
50. 123I reaction at a compact cyclotron. Int J Appl Radiat Isot 1981; 32:581-587.
51. Parry R, Schneider D, Hudson D, et al. Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. Cancer Res 2005; 65:8397-8405.
52. Buchholz HG, Herzog H, Forster GJ, et al. PET imaging with yttrium-86: comparison of phantom measurements acquired with different PET scanners before and after applying background subtraction. Eur J Nucl Med Mol Imaging 2003; 30:716-720.
53. 3-octreotide (SMT487)-a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003; 30:510-518.
54. 111In radiolabels. J Nucl Med 2001; 42:1281-1287.
55. 11), a cyclized peptide analog of a-MSH. J Med Chem 2005; 48: 2985-2992.
56. Pentlow KS, Finn RD, Larson SM, et al. Quantitative imaging of yttrium-86 with PET. The occurrence and correction of anomalous apparent activity in high density regions. Clin Positron Imaging 2000; 3:85-90.
57. Roesch F, Qaim SM, Stoecklin G. Production of the positron emitting radioisotope yttrium-86 for nuclear medical application. Appl Radiat Isot 1993; 44:677-681.
58. 86Y using a small biomedical cyclotron. Nucl Med Biol 2005; 32:891-897.
59. Clifford T, Boswell CA, Biddlecombe GB, et al. Validation of a novel CHX-A" derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A"-octreotide. J Med Chem 2006; 49:4297-1304.
60. 86Y-DTPA-octreotide. Nucl Med Biol 1997; 24:275-286.
61. 3He,xn)-processes. Radiochim Acta 1993; 61:1-8.
62. Reischl G, Rosch F, Machulla HJ. Electrochemical separation and purification of yttrium-86. Radiochim Acta 2002; 90:225-228.
63. Finn RD, McDevitt M, Ma D, et al. Low energy cyclotron production and separation of Yttrium-86 for evaluation of monoclonal antibody pharmacokinetics and dosimetry. In: Application of Accelerators in Research and Industry AIP Conference Proceedings. vol. 475. New York, NY: American Institute of Physics, 1999:991-993.
64. 111In labeled Herceptin. Nucl Med Biol 2002; 29:599-606.
65. 86Y purification using a three-column system. Nucl Med Biol 2004; 31:297-301.
66. 88Y at a small-sized cyclotron. Radiochim Acta 2002; 90:845-849.
67. 86Y for nuclear medical application. Appl Radiat Isot 1993; 44:677-681.
68. 89Zr-labeled monoclonal antibodies. J Nucl Med 2003; 44:1271-1281.
69. 90Y-zevalin biodistribution with positron emission tomography. Eur J Nucl Med Mol Imaging 2006; 33:1337-1345.
70. 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med 2005; 46:1898-1906.
71. 90Y-labeled monoclonal antibodies in xenograft-bearing nude mice. J Nucl Med 2003; 44:1663-70.
72. Dejesus OT, Nickles RJ. Production and purification of zirconium-89, a potential PET antibody label. Appl Radiat Isot 1990; 41:789-90.
73. 89Zr for antibody labeling and positron emission tomography. J Labelled Compd Radiopharm 1986; 23:1297-1298.
74. Zweit J, Downey S, Sharma HL. Production of no-carrier-added zirconium-89 for positron emission tomography. Appl Radiat Isot 1991; 42:199-201.
75. 89Zr for the labeling of antibodies with a positron emitter. Appl Radiat Isot 1994; 45:1143-7.
76. Griffiths GL, Goldenberg DM, Roesch F, et al. Radio-labeling of an anti-carcinoembryonic antibody Fab' fragment (CEA-Scan) with positron-emitting radionuclide Tc-94m. Clin Cancer Res 1999; 5:3001s-3003s.
77. Bigott HM, Parent E, Luyt LG, et al. Design and synthesis of functionalized cyclopentadienyl tricarbonylmetal complexes for technetium-94m PET imaging of estrogen receptors. Bioconjug Chem 2005; 16:255-264.
78. Bigott HM, Prior JL, Piwnica-Worms DR, et al. Imaging multidrug resistance P-glycoprotein transport function using microPET with Technetium-94m-sestamibi. Mol Imaging 2005; 4:30-39.
79. Nickels RJ, Nunn AD, Stone CK, et al. Technetium-94m-teboroxime: synthesis, dosimetry and initial PET imaging studies. J Nucl Med 1993; 31:1058-1066.
80. 94mTc for positron emission tomography studies. Nucl Med Biol 2000; 27:323-328.
81. Bigott HM, Laforest R, Liu X, et al. Advances in the production, processing and microPET image quality of technetium-94m. Nucl Med Biol 2006; 33:923-933.
82. Smith MF, Daube-Witherspoon ME, Plascjak PS, et al. Device-dependent activity estimation and decay correction of radionuclide mixtures with application to Tc-94m PET studies. Med Phys 2001; 28:36-45.
83. Barker WC, Szajek LP, Green SL, et al. Improved quantification for Tc-94m PET imaging. IEEE Trans Nucl Sci 2001; 48:739-742.
84. Szajek LP, Der M, Divel J, et al. Production and radioassay of Tc-94m for PET studies. Radiochim Acta 2003; 91: 613-616.
85. Bonardi ML, Goeij JJM. How do we ascertain specific activities in no-carrier-added radionuclide preparations? J Radioanal Nucl Chem 2005; 263:87-92.
86. 212Pb]. Biochem J 1923; 17: 439-435.
87. Chievitz O, Bohr N, de Hevesy G. Radioactive indicators in the study of phosphorous metabolism in rats. Nature 1935; 136:754.
88. Eckelman WC, Kilbourn MR, Mathis CA. Discussion of targeting proteins in vivo: in vitro guidelines. Nucl Med Biol 2006; 33:449-451.
89. Eckelman WC, Mathis CA. Targeting proteins in vivo: in vitro guidelines. Nucl Med Biol 2006; 33:161-164.
90. Kung MP, Kung HF. Mass effect of injected dose in small rodent imaging by SPECT and PET. Nucl Med Biol 2005; 32(7):673-678.
91. Eckelman WC. Receptor Binding Radiotracers. Vols 1 and 2. Boca Raton, FL: CRC Press, 1982:1-80; 1-230.
92. Lederer CM, Hollander JM, Perlman I. Table of Isotopes. Sixth ed. New York: John Wiley & Sons, 1967.
93. 64Cu-labeled rhenium-cyclized a-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med 2007; 48:64-72.